Logo image
Cardiostimulant effects of urotensin-II in human heart in vitro
Journal article   Peer reviewed

Cardiostimulant effects of urotensin-II in human heart in vitro

Fraser D Russell, P Molenaar and D O'Brien
British Journal of Pharmacology, Vol.132(1), pp.5-9
2001
url
https://doi.org/10.1038/sj.bjp.0703811View
Published Version

Abstract

Pharmacology and Pharmaceutical Sciences human urotensin-II human heart coronary artery atrium ventricle
The effects of the recently identified human peptide urotensin-II (hU-II) were investigated on human cardiac muscle contractility and coronary artery tone. In right atrial trabeculae from non-failing hearts, hU-II caused a concentration-dependent increase in contractile force (pEC50=9.50.1; Emax=31.34.8% compared to 9.25 mM Ca2+; n=9) with no change in contraction duration. In right ventricular trabeculae from explanted hearts, 20 nM hU-II caused a small increase in contractile force (7.81.4% compared to 9.25 mM Ca2+; n=3/6 tissues from 2 out of 4 patients). The peptide caused arrhythmic contractions in 3/26 right atrial trabeculae from 3/9 patients in an experimental model of arrhythmia and therefore has less potential to cause arrhythmias than ET-1. hU-II (20 nM) increased tone (17.9% of the response to 90 mM KCI) in 7/7 tissues from 1 patient, with no response detected in 8/8 tissues from 2 patients. hU-II is a potent cardiac stimulant with low efficacy.

Details

Metrics

1 File views/ downloads
796 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Pharmacology & Pharmacy

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image